Company: OSRH
Filing Date: 2025-01-24
Form Type: S-4/A
Source: 0001213900-25-006139
Chunk: 95

Company: OSR Holdings, Inc.
Filing Date: 2025-01-24
Form: S-4/A
Chunk 95
---
 market and sell our pharmaceutical products, we may not be able to generate pharmaceutical product revenue. •Our investment strategy and future growth relies on a number of assumptions, some or all of which may not be realizesd. Risks Related to New OSR Holdings’ Requirements for Additional Capital •We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs, future commercialization efforts and/or other operations. Risk Related to New OSR Holdings’ Management of the Business and Operations •We will incur increased costs as a result of operating as a public company, and our management will devote substantial time to compliance with its public company responsibilities and corporate governance practices. •New OSR Holdings’ management team has limited experience managing and operating a U.S. public company. Risks Related to International Operations of New OSR Holdings’ Business •If economic conditions in South Korea deteriorate, our current business and future growth could be materially and adversely affected. Risks Related to the Development of New OSR Holdings’ Product Candidates •Our business includes subsidiaries that are developing oral immunotherapies for the treatment of cancer and design -augmentedbiologics. These companies have a limited operating history, and their programs are in early stages of development. This may make it difficult to evaluate our prospects and likelihood of success. Risks Related to New OSR Holdings’ Reliance on Third Parties •We currently outsource, and intend to continue to outsource, much of our discovery, clinical development, and manufacturing functions to third -partyproviders or consultants. Outsourcing these functions has significant risks, and our failure to manage these risks successfully could materially adversely affect our business, results of operations, and financial condition. Risks Related to New OSR Holdings’ Intellectual Property •If we are unable to obtain and maintain patent and other intellectual property protection for our technology and product candidates or if the scope of the intellectual property protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets. The risks summarized above or described in full below are not the only risks that we face. Additional risks and uncertainties not presently known to us, or that we currently deem to be immaterial, may also materially adversely affect our business, financial condition, results of operations, and future growth prospects. 43

SELECTED HISTORICAL FINANCIAL DATA OF BLAC The information presented below is derived from